Trump’s Department of Government Efficiency will ironically require two men to run it14 November 2024
Rebate Game Played By PBMs And Drug Makers Limits Biosimilar CompetitionBy Press Room10 November 2024 Beginning in 2023, five years after their European counterparts, patients in the United States prescribed the autoimmune disease treatment Humira…
Biosimilars Are Making Inroads In U.S., But It’s Still A Bumpy RideBy Press Room4 November 2024 Biosimilars offer clinically effective treatment alternatives to branded reference drugs at a lower cost. These products are making inroads in…
Medicare Patient Access To Humira-Referenced Biosimilars Still Falls ShortBy Press Room5 February 2024 According to a federal government Medicare Payment Advisory Commission report published last month, more than 40% of Medicare beneficiaries still…